Info

🌱 來自：marginal zone lymphoma

treatment-of-marginal_zone_lymphoma

看這篇

Merli M, Arcaini L. Management of marginal zone lymphomas. Hematology American Society of Hematology Education Program. 2022;2022(1):676-687. doi:10.1182/hematology.2022000362

• In some cases, tx of underlying etiology can result in MZL regression

• H. pylori eradication w/ abx for gastric ENMZL (not effective if t(11;18) present or if there is muscularis or perigastric LN involvement), HCV for splenic MZL, doxycycline for ocular or cutaneous Borrelia-assoc ENMZL

• Localized dz common, can be tx curatively irrespective of sx often w/ limited RT

• Adv stage MZL is a chronic condition (typically incurable). Surveillance vs. tx is based on presence of ≥1 GELF, NCCN or similar criteria (like follicular lymphoma)

• Transformation:

  • 5–10% transform to aggressive large-cell lymphoma often signaled by
    • rapid ↑ LN,
    • new B sx,
    • or ↑ LDH.
  • Consider FDG PET directed bx, tx like DLBCL

• Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

• rr-rx-MZL

• CCO_ONC_2022_BDCommunity_CSR_BCellAgentsBTK_PDF2.pdf

• Use of anti-infectious regimens in patients with MZLs